Wells Fargo & Company Taysha Gene Therapies, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 69,742 shares of TSHA stock, worth $147,155. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,742
Previous 7,408
841.44%
Holding current value
$147,155
Previous $21,000
642.86%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding TSHA
# of Institutions
107Shares Held
136MCall Options Held
65.4KPut Options Held
41.7K-
Rtw Investments, LP New York, NY18.8MShares$39.7 Million0.7% of portfolio
-
Avoro Capital Advisors LLC New York, NY18.7MShares$39.4 Million0.57% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$24.8 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$22.9 Million0.37% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$19 Million2.21% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $102M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...